Geratherm Medical AG

GME

Equity

ISIN DE0005495626 / Valor 1091371

Xetra (2025-11-21)

EUR 3.37+1.51%

Geratherm Medical AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Geratherm Medical AG is an international medical technology company with a focus on developing innovative products for stroke prevention. The company has a strong academic and clinical network that complements its core competencies in mathematics, physics, and medicine. Geratherm's products, including spirometry, pulmonary function tests, and cardiopulmonary stress tests, are all developed and produced in Germany to meet high quality standards for pulmonologists, cardiologists, internists, sports medicine specialists, and natural scientists. In addition to medical devices, Geratherm also offers consumer products under the Geratherm® brand, such as clinical thermometers, blood pressure monitors, and pregnancy tests, which are available in pharmacies, retail outlets, and online shops. The company also provides innovative solutions like the MR diagnostics incubator system nomag®IC advanced for newborns and premature babies, allowing for non-invasive magnetic resonance imaging. With products for both private and professional users in various healthcare settings, Geratherm aims to meet the diverse needs of its customers worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue and Earnings Growth

For the first half of 2025, Geratherm Medical AG achieved Umsatzerlöse of approximately EUR 8.0 million, up by 13.2% year-on-year. The Rohergebnis increased by 7.9% to around EUR 5.275 million, while EBITDA rose sharply from EUR 217,000 to EUR 572,000, and EBIT turned positive at EUR 12,000 compared to a loss in the previous period.

Regional and Product Performance

Regionally, the European market outperformed with a +27.3% increase, and South America posted an impressive +181.4% growth. In terms of products, while the Healthcare Diagnostic segment showed a slight decline (-1.5%), the Respiratory segment increased by 17.4% and Incubator Systems nearly doubled its revenue (+91.8%) driven by successful MDR certification. The USA market remained stable, whereas the Middle East and other regions faced declines.

Profitability and Efficiency Improvements

The group result improved significantly to a loss of EUR 237,000 from EUR 1.404 million negative in the prior period, and earnings per share improved to -0.04 EUR from -0.26 EUR. Although the gross margin saw a slight decline (65.7% versus 69.0%), operational efficiencies were gained through the reduction of prior order backlogs.

Financial Stability and Liquidity

Geratherm Medical AG maintained a robust financial position with an equity ratio of 74.7% and stable liquidity totaling EUR 9.6 million. The operating cash flow stood at EUR 862,000, reaffirming the company's capacity to manage through challenging economic conditions.

Outlook

Looking ahead in 2025, while production capacity in some segments is not yet fully utilized (with the continuation of measures like extended short-time work), strong demand for Respiratory products and positive trends in the Incubator Systems segment set a promising tone for future performance.

Summarized from source with an LLMView Source

Key figures

23.0%1Y

-42.7%3Y

-70.2%5Y

Performance

90.8%1Y

64.0%3Y

54.0%5Y

Volatility